153.36

1.87% -2.92

Belite Bio Inc Adr (BLTE)

Overview News Price History Discussions Forecast

Belite Bio Inc Adr stock is traded at $153.36, with a volume of 172.38K. It is down -1.87% in the last 24 hours and up +1.72% over the past month. Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Previous Close:

$156.28

Open:

$157.11

24h Volume:

172.38K

Relative Volume:

0.93

Market Cap:

$6.15B

Revenue:

Net Income/Loss:

$-77.61M

P/E Ratio:

-66.74

EPS:

-2.2979

Net Cash Flow:

1W Performance:

+2.19%

1M Performance:

+1.72%

6M Performance:

-6.81%

1Y Performance:

+147.95%

1-Day Range:

$151.97

$157.11

1-Week Range:

$150.63

$161.43

52-Week Range:

$60.00

$200.00

Belite Bio Inc Adr Stock (BLTE) Company Profile

Name

Belite Bio Inc Adr

Sector

Healthcare (1071)

Industry

Biotechnology (598)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-08-10

Latest SEC Filings

BLTE's Discussions on Twitter

Compare BLTE vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BLTE Belite Bio Inc Adr	153.36	6.15B	0	-77.61M	0	-2.2979
VRTX Vertex Pharmaceuticals Inc	477.36	121.16B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	656.01	68.78B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.22	57.44B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	189.23	40.23B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	271.77	36.28B	4.29B	577.22M	641.34M	4.2086

Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-26-26	Initiated	BofA Securities	Buy
Jan-06-26	Initiated	Morgan Stanley	Overweight
Dec-02-25	Upgrade	Mizuho	Neutral → Outperform
Nov-24-25	Resumed	Cantor Fitzgerald	Overweight
Nov-20-25	Initiated	Mizuho	Neutral
Dec-14-23	Initiated	Maxim Group	Buy
Jul-28-23	Initiated	Cantor Fitzgerald	Overweight
Jul-26-23	Initiated	SVB Securities	Outperform
Aug-01-22	Initiated	H.C. Wainwright	Buy
Jul-01-22	Initiated	The Benchmark Company	Buy

View All

Belite Bio Inc Adr Stock (BLTE) Latest News

Jul 22, 2026

Belite Bio Conference Highlights Tinlarebant Data and New Hope for Retinal Diseases - Yahoo Finance

Jul 22, 2026

Belite Bio stock price target maintained at $200 by H.C. Wainwright - Investing.com UK

Jul 22, 2026

Belite Bio stock price target maintained at $200 by H.C. Wainwright By Investing.com - Investing.com Australia

Jul 22, 2026

Belite Bio (BLTE) Leerink’s Global Healthcare Conference 2025 Summary - Quartr

Jul 22, 2026

Jul 20, 2026

Belite Bio presents additional Phase 3 trial data for tinlarebant By Investing.com - Investing.com South Africa

Jul 20, 2026

Belite Bio presents additional Phase 3 trial data for tinlarebant - Investing.com

Jul 20, 2026

Belite Bio (BLTE) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $BLTE - MarketBeat

Jul 20, 2026

Jul 18, 2026